Signal active
Organization
Contact Information
Overview
ReVision Optics, Inc. designs, manufactures, and delivers implantable products for the treatment of presbyopia. It offers PRESBYLENS Corneal Inlay, a refractive surgery solution to correct vision lost by the natural aging process called presbyopia. The company serves the ophthalmology professionals. ReVision Optics, Inc. was formerly known as IntraLens Vision, Inc. and changed its name to ReVision Optics, Inc. in 2005. The company was founded in 1996 and is based in Lake Forest, California.
About
Biotechnology, Health Care, Medical, Manufacturing, Product Design
1996
51-100
Headquarters locations
United States, North America
Social
N/A
Profile Resume
ReVision Optics headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Manufacturing, Product Design sector. The company focuses on Biotechnology and has secured $39.0B in funding across 200 round(s). With a team of 51-100 employees, ReVision Optics is actively contributing to advancements in Biotechnology. Their latest funding round, Series D - ReVision Optics, raised $35.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
10
4
0
$194.9M
Details
8
ReVision Optics has raised a total of $194.9M in funding over 8 rounds.
Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
---|---|---|---|---|
2007 | Late Stage Venture | 25.0M | ||
2013 | Late Stage Venture | 55.0M | ||
2013 | Late Stage Venture | 15.0M | ||
2010 | Late Stage Venture | 35.0M |
Investors
ReVision Optics is funded by 47 investors.
Investor Name | Lead Investor | Funding Round | Partners |
---|---|---|---|
Renee Ryan | - | FUNDING ROUND - Renee Ryan | 15.0M |
Johnson & Johnson Development Corporation | - | FUNDING ROUND - Johnson & Johnson Development Corporation | 15.0M |
ReVision Optics | - | FUNDING ROUND - ReVision Optics | 15.0M |
RMI Partners | - | FUNDING ROUND - RMI Partners | 15.0M |
Recent Activity
There is no recent news or activity for this profile.